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ABSTRACT
The SET (I2PP2A) oncoprotein is a potent inhibitor of protein phosphatase 2A 
(PP2A) that regulates many cell processes and important signaling pathways. Despite 
the importance of SET overexpression and its prognostic impact in both hematologic 
and solid tumors, little is known about the mechanisms involved in its transcriptional 
regulation. In this report, we define the minimal promoter region of the SET gene, and 
identify a novel multi-protein transcription complex, composed of MYC, SP1, RUNX1 
and GATA2, which activates SET expression in AML. The role of MYC is crucial, since 
it increases the expression of the other three transcription factors of the complex, 
and supports their recruitment to the promoter of SET. These data shed light on a 
new regulatory mechanism in cancer, in addition to the already known PP2A-MYC and 
SET-PP2A. Besides, we show that there is a significant positive correlation between 
the expression of SET and MYC, RUNX1, and GATA2 in AML patients, which further 
endorses our results. Altogether, this study opens new directions for understanding 
the mechanisms that lead to SET overexpression, and demonstrates that MYC, SP1, 
RUNX1 and GATA2 are key transcriptional regulators of SET expression in AML.
INTRODUCTION
Acute myeloid leukemia (AML) results from multiple 
genetic and epigenetic alterations in hematopoietic stem 
cells, and is characterized by a differentiation blockade of 
the myeloid hematopoietic progenitor cells accompanied 
by uncontrolled proliferation [1]. Although major 
improvements have been achieved in the overall survival 
of adult cases ≤60 years, most of the patients are older 
than 60 years, and in this group only 5-15% are cured [2, 
3]. Therefore, it is necessary to develop more effective 
treatment strategies for this disease.
PP2A, one of the main serine/threonine phosphatases 
in mammalian cells, is a tumor suppressor which regulates 
several essential functions and counteracts most of the kinase-
driven intracellular signaling pathways [4]. Our group and 
others have demonstrated that overexpression of SET, a 
potent PP2A endogenous inhibitor, is a recurrent event that 
causes PP2A inactivation in hematological neoplasms [5–8]. 
The SET gene (also known as I2PP2A or TAF-1β; 9q34) 
encodes a multifunctional protein that mediates essential 
functions in cell cycle control [9], cell migration [10], 
apoptosis [11–13], differentiation [14], DNA repair [15], 
DNA replication [16], transcription and histone acetylation 
[17–20], as well as chromosome modeling [21, 22]. SET was 
first identified as an oncogene fused with the nucleoporin 
NUP214 (CAN) in acute undifferentiated leukemia [23], 
and soon after, it was described as a PP2A inhibitor [24]. 
SET binds directly to the PP2A catalytic subunit, impairing 
its tumor suppressor enzymatic activity [5, 24–26]. Recent 
studies have revealed how SET inhibition of PP2A depends 
on SET sub-cellular localization [10, 27]. In steady-state 
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cells, SET levels are low and it localizes mainly in the nucleus 
through the interaction with importin alpha3/beta [28]. In 
dividing cells, SET expression increases and it accumulates 
in the cytoplasm [29]. The nucleus-cytoplasm shuttling of 
SET is controlled by the interaction with exportin CRM1 
[30], and by the phosphorylation of serine 9 in one of the 
SET nuclear localization signals [10, 31, 32]. Interestingly, 
the anticancer activity of FTY720 and OP449, two recently 
discovered PP2A-activating drugs, depends on the interaction/
sequestration of SET, pointing out the significance of this 
oncogene in AML [26, 33–35].
Nevertheless, despite the importance of SET, and 
the prognostic impact of SET overexpression in both solid 
and hematologic tumors [5, 7, 8, 36–39], little is known 
about the mechanisms involved in the transcriptional 
regulation of this oncogene. In this report, we study 
the promoter region of SET in order to investigate the 
mechanisms that lead to SET overexpression in AML. We 
determine its minimal functional promoter region, and 
demonstrate that MYC, SP1, RUNX1 and GATA2 form 
a multi-protein transcriptional complex that is involved in 
the transcriptional activation of SET in AML.
RESULTS
SET knockdown by shRNA and siRNA results 
in the re-establishment of PP2A activity and 
consequent inhibition of AKT and ERK cell 
proliferation pathways
To explore the functional role of SET in AML, 
we transfected the AML cell lines HL-60 and HEL 
with specific shRNA and siRNAs that efficiently down-
regulate SET levels. SET depletion led to a decrease in 
cell viability and clonogenic growth (Figure 1A and 1B, 
Supplementary Figure S1A, S1B, S1F, S1G), accompanied 
by an increase in apoptosis (Supplementary Figure S1C, 
S1H). Furthermore, PP2A activity was re-established, 
producing the inactivation of AKT and ERK, both targets 
of PP2A (Figure 1C, 1D and Supplementary Figure S1D, 
S1E, S1I, S1L). In vivo studies with mouse xenografts 
injected subcutaneously with SET shRNA-infected 
HL-60 cells produced tumors that grew at a slower rate 
(Figure 1E), and presented smaller and milder features 
compared to control shRNA cells (Figure 1F, 1G). To 
confirm that all these evidences were due exclusively to 
the depletion of SET, we analyzed the levels of CIP2A, 
another endogenous inhibitor of PP2A [40], and SETBP1, 
which is known to stabilize SET at protein level in AML 
[41]. No significant changes were found for CIP2A, 
whereas SETBP1 was significantly reduced (Figure 1D), 
suggesting a possible regulation of SETBP1 by SET. 
Taken together, these results show that SET depletion 
leads to a reduction in cell growth and an increase in 
apoptosis by re-activating PP2A in AML cells, confirming 
the importance of SET in AML.
Identification and characterization of the SET 
minimal promoter region
As indicated above, SET is overexpressed in 
different solid and hematological tumors; however, 
the causes of this overexpression are still unknown. To 
address this issue, we investigated the functional promoter 
region of SET. First, we performed an in silico analysis of 
1000 bp 5′ upstream of its TSS (transcription start site) for 
putative binding sites for transcription factors (TFs). This 
analysis revealed that RUNX1, GATA2, MYC and SP1, 
four TFs with essential roles in hematopoiesis [42–45], 
could have a role in the regulation of SET. The SET distal 
promoter region (-932/-699bp) contains DNA motifs for 
RUNX1 and GATA2, and the proximal promoter region 
(-318bp/TSS) for SP1 and MYC (Supplementary Figure 
S2). Upon assessing the expression of these TFs in six 
cell lines by Western blot (Supplementary Figure S3), we 
observed that all of them were present in AML cells, while 
non-AML cell lines lacked detectable RUNX1 expression, 
and showed low GATA2 expression.
Next, we analyzed this region using five different 
prediction algorithms in order to define the putative 
minimal promoter region (Supplementary Figure S4). 
These data allowed us to generate serial 5′ and 3′ 
truncation constructs that were cloned upstream of the 
luciferase reporter gene, and transfected into HL-60, HEL 
and HEK293t cells. Our results showed that the region 
between -318bp and the TSS encompassed the maximum 
promoter activity in the three cell lines analyzed (Figure 
2A and Supplementary Figure S5A and S6). This is in 
agreement with the region most recurrently predicted as 
promoter by the different algorithms used for the in silico 
analysis. In HEL, the -932/TSS region presented weaker 
activity than in the other cells, suggesting the presence of 
a silencer element particularly active in this cell line. The 
activity of pGL3-1005/-683bp was almost absent, as in 
the case of the empty pGL3b vector. Sequence analysis of 
the -318/TSS region revealed the presence of three E-box 
sequences, which are potential binding sites for TFs such 
as MYC [46, 47]. To narrow down the region involved 
in the regulation of SET, we performed luciferase assays 
with sequence mutants that were defective in one, two, or 
all three E-box sequences. As displayed in Supplementary 
Figure S7, constructs defective for E-boxes n.1 and 2 reduce 
promoter activation by 20% in HL-60 and by 30% in HEL 
cell lines, implicating these E-box sequences as significant 
sites for TF binding and regulation of SET transcription. 
Taken together, these results show the importance of the 
-318bp/TSS region in the transcription of the SET gene.
Chromatin immunoprecipitation (ChIP) and re-ChIP 
assays confirmed the binding of MYC, together with SP1, 
RUNX1 and GATA2 to the -318/-144bp region of SET 
promoter in HL-60 and HEL cells, where they co-localize 
with RNA polymerase II (RNA pol II) (Figure 2B, 2C 
and Supplementary Figure S5B, S5C). Intriguingly, we 
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found that RUNX1 and GATA2 bind more efficiently to 
the -318/-144bp region than to the distal promoter region, 
although there are no DNA motifs for these TFs in this 
region. Additionally, using antibodies that recognize histone 
acetylation (H3K4 acetylation), we confirmed that the 
-318bp/TSS is a transcriptionally active region in AML.
MYC and SP1 enhance the expression of SET 
in AML
To investigate the role of MYC and SP1 in SET 
transcription, we silenced the expression of these two 
TFs with siRNAs. Luciferase assays showed a significant 
decrease in SET promoter activity, along with reduced 
SET expression at mRNA and protein levels (Figure 
3A–3C, Figure 4A-4C and Supplementary Figures 
S8A-S8C and S9A-S9C). Remarkably, depletion of 
MYC caused a general reduction of all the other TFs 
involved in the transcription of SET, and also of the SET-
related proteins CIP2A and SETBP1 (Figure 3C, and 
Supplementary Figure S8C). The SP1 reduction with 
SP1#1 siRNA had a similar effect, although in HEL cell 
line only (Supplementary Figure S9C). In addition, both 
SP1 and MYC knockdown decreased cell proliferation 
and re-activated PP2A (Figure 3D–3E, Figure 4D-4E, 
and Supplementary Figures S8D-S8E and S9D-S9E), 
indicating that these TFs activate the expression of SET, 
resulting in PP2A inactivation in AML cells. We also 
evaluated the effect of 10058F4, an inhibitor of MYC, 
on SET transcriptional regulation. Both SET promoter 
activity and levels (mRNA and protein) decreased 
markedly after treatment with 10058F4, mirroring the 
Figure 1: Depletion of SET results in the reduction of cell proliferation and clonogenic growth in AML. A. Cell 
proliferation curve assessed by MTS assay in HL-60 cells with silenced SET shRNA (shSET) compared to control shRNA (shCTRL). B. 
Soft-agar clonogenic growth assay (colony forming capacity in soft-agar media), in HL-60 cells with shSET compared to control shRNA. 
C. PP2A activity assay with paired Western blot detection of the amount of PP2A immunoprecipitated. Data are the means ± SD of three 
independent experiments. D. Representative Western blot of the phosphorylation state of PP2A targets ERK (T202/Y204) and AKT (T308), 
CIP2A and SETBP1, together with the endogenous levels of SET, in cells stably transfected with shRNA of SET versus control. GRB2 and 
Tubulin were used as loading control. Numbers indicate the protein quantification relative to GRB2 or Tubulin and assessed using Image J 
software (NIH, USA). Tumor volumes E. and tumor weights F. in Rag2-/- γc-/- mice xenografts of HL-60 cells stably transfected with SET 
or control shRNAs, and the corresponding picture of the extracted tumors G.. Statistically significant differences are indicated: *P < 0.05, 
**P < 0.01, ***P < 0.001, Student’s t-test analysis.
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results obtained with the siRNA of MYC; furthermore, 
the PP2A function was re-established in HL-60 and HEL 
cells (Supplementary Figure S10 and S11). Finally, the 
inactivation of MYC produced a major decrease of SP1 
(by 70%) and a more moderated reduction of GATA2 (by 
20%) in HEL cells (Supplementary Figure S11C), whilst 
no significant effects on these TFs were found in HL-60 
(Supplementary Figure S10C). These results confirm that 
MYC increases the expression of SET in AML, resulting 
in PP2A inactivation.
SP1 is known to interact with MYC [48–50] and 
together they regulate the expression of several genes 
[51]. We therefore performed co-immunoprecipitation (co-
IP) experiments and confirmed that SP1 binds to MYC 
in AML (Figure 5A). Altogether, our results demonstrate 
that MYC activates the expression of TFs such as SP1, 
forming a complex that enhances the transcription of SET, 
and eventually, the expression of CIP2A and SETBP1, 
resulting in PP2A inactivation and increasing cell 
proliferation in AML.
Figure 2: RUNX1, GATA2, SP1, MYC and RNA Pol II co-localize on the SET minimal functional promoter region 
(-318bp-TSS). Luciferase assays with the SET promoter constructs in HL-60 cells 48h after transfection. A. Results represent relative Firefly/
Renilla luciferase activities considering the empty pGL3basic vector as 1. Data are the means ± SD of three independent experiments. Asterisks 
denote the statistical significance of the differences between pGL3b and the constructs or between the paired constructs where indicated. *P < 
0.05, **P < 0.01, ***P < 0.001, Two-way ANOVA and Bonferroni tests were used. B. Chromatin Immunoprecipitation assay performed in the 
HL-60 cell line. Two promoter sub-regions were defined, a distal region (-932/-587bp) enriched with RUNX1 and GATA2 predicted binding 
sites and the minimal functional promoter region (-318/-144bp) with SP1 and MYC E-box putative binding sites. A distal genomic region on the 
same chromosome 9 was used as a negative control. QRT–PCR results were calculated using the 2-Ct method and they are presented as the fold 
enrichment of chromatin DNA precipitated by the specific antibody versus chromatin DNA precipitated by a non-related IgG. Values are the 
mean of three independent experiments. Asterisks denote the statistical significance differences where indicated. *P < 0.05, **P < 0.01, ***P < 
0.001, Two-way ANOVA and Bonferroni tests were used. C. ChIP-re-ChIP assay performed in the HL-60 cell line. Technical procedures were 
carried out as described in Materials and Methods. MYC antibody was used for the first immunoprecipitation, and SP1, RUNX1, and GATA2 
antibodies were used for the second immunoprecipitation. Re-ChIP assay values are the mean of two independent experiments.
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MYC, SP1, RUNX1 and GATA2 form a multi-
protein transcription complex that activates the 
expression of SET
Since the ChIP and re-ChIP assays showed that 
RUNX1 and GATA2 bind to a region of the SET promoter 
that harbors predicted binding sites for SP1 and MYC, we 
performed immunoprecipitation experiments and confirmed 
the association between RUNX1 and GATA2, and their 
interaction with SP1 and MYC in HL-60 and HEL cells 
(Figure 5B–5D). Next, we further investigated the role of 
RUNX1 and GATA2 in the regulation of SET transcription. 
Knockdown of either RUNX1 or GATA2 markedly reduced 
SET promoter activity (mostly in the -318bp and -163bp 
regions), and mRNA and protein expression (Figure 6A–6C, 
Supplementary Figure S12A-S12C and Supplementary 
Figure S13). Moreover, as expected, PP2A activity was 
reconstituted and the cell proliferation rate decreased (Figure 
6D, 6E and Supplementary Figure S12D, S12E). Single or 
simultaneous depletion of GATA2 and RUNX1 weakened 
the levels of MYC and SP1, revealing a complicated 
network of regulation among the TFs studied here that may 
vary depending on the cell line. In addition, overexpression 
of RUNX1 and GATA2 in HEK293t cells, which displayed 
undetectable and low levels of these TFs, respectively 
(Supplementary Figure S14), significantly increased the 
activity of the SET promoter and the amount of SET mRNA 
and protein, together with a gain in cell proliferation rate 
and PP2A inactivation (Supplementary Figure S14). No 
significant changes in SET expression were found when 
these two TFs were separately overexpressed (data not 
shown), suggesting that RUNX1 and GATA2 co-operation is 
necessary to activate SET. These data, together with the ChIP 
results, suggest the presence of a transcription complex that 
Figure 3: MYC depletion significantly reduces SET transcription and re-activates PP2A in AML. A. Luciferase assay in 
HL-60 cells transfected with a siRNA for MYC silencing. B. SET mRNA expression assessed by QRT-PCR. C. Western blot analysis of the 
corresponding protein levels of MYC, SP1, GATA2, RUNX1, SETBP1, CIP2A and SET. β-Actin detection was used as loading control. 
Numbers indicate the protein quantification relative to β-Actin and assessed using Image J software (NIH, USA). D. Cell proliferation rates. 
E. PP2A activity levels with paired western blot results of the amount of PP2A immunoprecipitated in each condition. Data are the means 
± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, Students t-test analysis.
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comprises at least MYC, SP1, RUNX1 and GATA2, which 
binds to the SET promoter and enhances its expression, along 
with the expression of each members of the aforementioned 
complex that may be the cause of PP2A inactivation in AML.
MYC recruits RUNX1 and GATA2 and allows 
SET transcription in AML
As the region of the SET promoter with maximum 
activity contains MYC binding sites, and these TFs interact 
among them, we studied whether depletion or inhibition 
of MYC could affect the formation and localization of 
the transcriptional complex of MYC, SP1, RUNX1 and 
GATA2. Co-IP and ChIP experiments in cells transfected 
with a siRNA for MYC show that the decrease of MYC, and 
consequentially reduction of RUNX1, GATA2 and SP1, did 
not totally prevent the formation of the multi-protein complex 
in the cells (Figure 7A, 7D). However, its localization on 
the SET functional promoter was entirely abolished (Figure 
7B, 7E). Similar results were obtained in AML cell lines 
treated with the MYC inhibitor 10058F4. The inhibition and 
consequent reduction of MYC significantly reduced RUNX1 
and GATA2 recruitment on the SET functional promoter 
(by 2.7 and 1.5 times p< 0.001, respectively in HL-60 cells 
(Figure 7C); and by 2.39 and 1.68 times p< 0.001 in the HEL 
cell line, (Figure 7F), whereas no substantial differences were 
found relative to SP1 or RNA pol II binding.
SET expression correlates with MYC, RUNX1 
and GATA2 expression in AML patients
To evaluate the clinical relevance of our results, we 
analyzed the data from a series of patients with de novo AML 
that had been previously reported [8, 52]. We found a positive 
correlation between SET and GATA2 expression levels in 167 
patients (R= 0.256, p= 0.001; Figure 8A-8C), corroborating 
Figure 4: SP1 activates SET transcription in AML. A. Luciferase assay in HL-60 cells transfected with two different siRNAs, 
siRNA#1 and siRNA#2. B. SET mRNA expression assessed by QRT-PCR. C. Western blot analysis of the corresponding protein levels of 
SP1, MYC, GATA2, RUNX1, SETBP1, CIP2A and SET. β-Actin was used as loading control. Numbers indicate the protein quantification 
relative to β-Actin and assessed using Image J software (NIH, USA). D. Cell proliferation rates. E. PP2A activity levels with paired western 
blot results of the amount of PP2A immunoprecipitated in each condition. Values are the mean ± SD of three independent experiments. *P 
< 0.05, **P < 0.01, ***P < 0.001, Students t-test analysis.
Oncotarget7www.impactjournals.com/oncotarget
the association between these two genes in AML. We next 
investigated the expression of SET, RUNX1, GATA2, SP1 and 
MYC in 182 samples of adult patients with de novo AML 
recently reported by the Cancer Genome Atlas [53]. There 
was a positive correlation between SET and either RUNX1 
(R=0.437, p< 0.001) or GATA2 (R=0.339, p< 0.001), though 
the strongest significance was obtained when comparing SET 
and MYC expression (R=0.505, p< 0.001; (Figure 8D–8G). 
There was no significant correlation between SET and SP1 
levels (R= -0.089, p= 0.234; data not shown).
DISCUSSION
Despite the importance of SET in both solid and 
hematologic tumors, little is known about the mechanisms 
involved in the transcriptional regulation of this oncogene. 
Here, we have studied the promoter region of SET in 
order to investigate the mechanisms that lead to SET 
overexpression in AML. We have characterized for the 
first time a minimal promoter region in the human SET 
gene, and we have demonstrated that MYC, SP1, RUNX1 
and GATA2 form a multi-protein transcriptional complex 
that is involved in the transcriptional activation of this 
gene.
In this report, we have first confirmed that SET is 
an important regulator of proliferation and apoptosis in 
AML. Our experiments with shRNA and siRNAs showed 
the function of SET as an inducer of cell proliferation (by 
activating AKT and ERK pathways), and as an inhibitor of 
apoptosis in AML cells, through its binding and inhibition 
of PP2A. Although other in vivo model should be used to 
address the role of SET in leukemogenesis, these results 
are consistent with published data in chronic myeloid 
leukemia [5, 54] and other human cancer cells [5, 7, 8, 37, 
39, 55], and strongly suggest that SET deregulation may 
play an important role in the pathogenesis of leukemia in 
AML patients.
We and others have previously reported that SET 
overexpression is associated with poor prognosis in 
AML and other malignancies [5, 7, 8, 37]. Despite these 
findings, which underscore the clinical relevance of 
SET expression, little is known about the causes of its 
overexpression in cancer. This prompted us to analyze the 
transcriptional regulation of SET. Here, we have defined 
the SET minimal promoter region (-318bp before the TSS), 
and found that this region is bound and activated by MYC 
and SP1, together with RUNX1 and GATA2. In silico 
analysis found no DNA motifs for RUNX1 and GATA2 
in this region of SET promoter, and we hypothesized and 
confirmed that these TFs could form a complex with MYC 
and SP1. Furthermore, our results indicate that MYC is 
interacting with and recruiting SP1, RUNX1, and GATA2 
on the chromatin; nevertheless, we cannot say whether 
they bind to the DNA directly or through MYC. Moreover, 
our results show that the depletion of any of these four 
TFs results in a significant reduction of SET expression. 
Figure 5: Transcriptional regulation complex that activates SET expression in AML. Immunoprecipitation experiments in the 
HL-60 (left) and HEL (right) cell lines were performed using anti-SP1 or non-specific IgGs (used as a control). Then, the immunoprecipitates 
were analyzed for the presence of SP1 and MYC. A. Immunoprecipitation experiment using anti-RUNX1 followed by the analysis for the 
presence of RUNX1 and GATA2. B. Immunoprecipitation experiment using anti-GATA2 followed by the analysis for the presence of SP1, 
MYC, RUNX1 and GATA2. C. Immunoprecipitation experiment using anti-RUNX1 followed by the analysis for the presence of SP1, MYC 
and RUNX1. D. Input represents 30mg of total lysate. The western blots here displayed are the representation of three independent experiments.
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Previous separate studies have reported collaboration 
either between SP1 and MYC [46, 49, 50] or between SP1 
and GATA2 [56, 57], or between RUNX1 and MYC [58]. 
Here, we have described the existence of a novel multi-
protein complex in which RUNX1 and GATA2 interact 
with MYC and SP1, and activates SET transcription in 
AML cells. Additionally, our results prompt us to speculate 
about the presence of an intricate network of regulations 
among these TFs, in which MYC activates the expression 
of SP1, RUNX1 and GATA2; RUNX1 and GATA2 increase 
the expression of MYC, and finally, SP1 increases the 
expression of GATA2. Likely, the expression of RUNX1 
and GATA2 is affected by other proteins, or by a general 
lessening of cell proliferation, and not exclusively by 
MYC. Still, our data show that MYC is crucial for the 
recruitment of RUNX1, GATA2 and SP1 to the proximal 
promoter of SET. MYC is a well-known target of PP2A, 
since its protein stability is reduced by PP2A-dependent 
dephosphorylation of Serine 62 [59, 60]. Consequently, 
the impairment of PP2A activity by SET prevents MYC 
degradation [61]. Our study supports the importance of 
MYC as a potential target in AML, discovering its ability 
to reduce PP2A enzymatic activity through the regulation 
of SET transcription, and possibly CIP2A and SETBP1, 
defining a new layer of regulation that exists in the 
connection PP2A-MYC and SET-PP2A in cancer.
Finally, correlation analyses show that SET expression 
associates with MYC, RUNX1 and GATA2 expression in 
AML patients, corroborating our data and highlighting 
their clinical importance. However, the expression of SP1 
Figure 6: RUNX1 and GATA2 co-activate the expression of SET, and inactivate PP2A in AML. A. Luciferase assay in HL-
60 cells transfected with siRNAs for RUNX1 and GATA2, alone or together. B. SET mRNA expression analyzed by QRT-PCR. Expression 
was normalized to the HPRT housekeeping gene. C. Corresponding protein expression levels of GATA2, RUNX1, MYC, SP1 and SET 
were assessed by western blot. β-Actin was used as loading control. Numbers indicate the protein quantification relative to β-Actin and 
assessed using Image J software (NIH, USA). D. Cell proliferation of HL-60 cells transfected with siRNA for RUNX1, GATA2 and RUNX1 
plus GATA2. E. PP2A activity levels with paired western blot analysis of the amount of PP2A immunoprecipitated in each condition. Values 
are the mean ± SD of three independent experiments. Asterisks indicate the statistical significance of the differences between the different 
constructs. *P < 0.05, **P < 0.01, ***P < 0.001, One-way ANOVA and Bonferroni post-hoc tests were used.
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does not correlate with SET expression. The reason for 
this finding remains unclear. It has been reported that SP1 
plays an important role in regulating cell proliferation by 
modulating the expression of several cell cycle regulatory 
proteins through specific sequences in G/C-rich promoter 
regions [62], and this is critical for transcriptional initiation 
of TATA-less promoters [63], such as the SET promoter. It 
can be hypothesized that SP1 acts as a housekeeping factor 
in AML cells, being constitutively present, and exerting 
different functions depending on the partners available 
to form multi-TF complexes. Supporting this hypothesis, 
the variability of SP1 expression in the data series of The 
Cancer Genome Atlas that we have analyzed is quite low 
(CV= 22.2 %) compared to that of MYC (66.9%), GATA2 
(67.5%) and RUNX1 (42.3%).
In summary, we have found that SET transcriptional 
regulation is controlled by at least four TFs. Interestingly, 
these are essential TFs that control different stages of 
hematopoiesis [42–45] and are frequently overexpressed in 
cancer [52, 62, 64–66]. Furthermore, our findings reveal a 
novel mechanism by which these TFs promote cancer. The 
simultaneous overexpression of MYC, SP1, RUNX1 and 
GATA2 would enhance the transcription of SET, which 
would trigger PP2A inactivation in AML, contributing to 
the leukemogenic phenotype. In this regard, treatments 
combining inhibitors for MYC, GATA2 and/or RUNX1 
could be more effective and could minimize the development 
of resistance by targeting two or more proteins in the same 
complex. Further preclinical investigation of these possible 
combinatorial therapies in AML is still needed.
Figure 7: SET transcriptional regulation in AML is MYC-dependent. A. Immunoprecipitation experiments using anti-RUNX1 
or non-specific IgGs in HL-60 cells. Cell extracts 48h after the electroporation with siRNA against MYC or scramble siRNA followed by 
the analysis for the presence of SP1, MYC, GATA2 and RUNX1. -Actin was used as loading control. B. ChIP assay performed in HL-60 
cells with siRNA against MYC. C. ChIP assay performed in HL-60 cells treated with MYC inhibitor 10058F4. Values are the mean ± SD 
of three independent experiments. Statistically significant differences are indicated: *P < 0.05, **P < 0.01, ***P < 0.001, Mann-Whitney U 
test. The same experiments were performed in the HEL cell line D, E, F.. G. Model illustrating the participation of RUNX1, GATA2, MYC 
and SP1 in the activation of SET transcription in AML.
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Figure 8: Correlation analysis of the SET and GATA2, RUNX1 and MYC expression in AML patients. A. SET 
and GATA2 mRNA expression levels in 167 AML patients assessed by QRT-PCR, and tested for correlation with SPSS 17.0 
using Spearman’s correlation test. The possible association between high/low GATA2 and SET mRNA expression levels was 
tested by Pearson’s chi square test, using the defined thresholds for SET and GATA2 expression previously described [8, 52]. 
SET expression in the two groups of patients according to GATA2 expression B. and in the two groups defined by SET expression 
levels C. are shown. Statistical analysis was performed with Mann-Whitney’s U test. The bar inside the boxes represents the 
median value, the limits of the box the interquartile range, the whiskers the range of expected values and (•) are outlier values. 
D-G. Analysis of SET, RUNX1, GATA2 and MYC expression in published high throughput data of adult de novo AML patients. 
mRNA expression values were extracted from data generated by the TCGA Research Network: http://cancergenome.nih.gov/. We 
analyzed the whole transcriptome of 182 AML samples using the Affymetrix HGU 133 Plus 2 microarray experiment provided 
by the TCGA Research Network: http://cancergenome.nih.gov/. R/Bioconductor [72] was used for the background correction and 
normalization of the samples using Robust Multichip Average (RMA) algorithm [73]. To filter out low expression probes, only 
those with log2-expression values above 5 in at least 30% of the samples were analyzed. In addition, the probesets 210231_x_at 
and 200630_x_at were removed from SET expression calculations due to their predicted unspecific partial binding to a transcribed 
region in chromosome 1. To calculate the expression values of each gene, the probesets that remained after these filtering steps 
were averaged. To arrange the samples by SET expression, this averaged value was used to set a percentile 70 thresholds, over 
which SET expression was considered high. Statistical analyses were performed with SPSS 17.0: RUNX1, GATA2 and MYC 
expression levels were tested for correlation with SET expression using the Spearman’s correlation test, and also compared 
between the high and low SET expression groups of patients by means of Student’s t-test or Mann-Whitney’s U test, depending 
on the distribution of each variable. Differences were considered significant when p< 0.05. The levels of mRNA expression in 
the SET high and SET low groups are represented for SET (D), RUNX1 (E), GATA2 (F), and MYC (G). The bar inside the boxes 
represents the median value, the limits of the box the interquartile range, the whiskers the range of expected values and (•) are 
outlier values. Correlation plots for SET expression vs. RUNX1, GATA2 and MYC expression levels are also shown (right panels).
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MATERIALS AND METHODS
Experimental animals
Rag2-/-γc-/- mice were bred in house and treated 
according to the guidelines established by the University 
of Navarra Animal Experimentation Ethics Committee 
(No.:138-11). Stably transfected SET shRNA or control 
shRNA AML cells were harvested and re-suspended at 2 x 
107 cells per ml in sterile phosphate-buffered saline. Two 
groups (each group, n= 8) of 6 week-old female Rag2-/-γc-/- 
mice were subcutaneously injected at the shoulder with 
0.2 ml of the cell suspensions, one group for SET shRNA 
expressing cells and another for the control shRNA cells. 
Tumor growth was first measured 4 days after injection 
and then every day until the end of the experiment. Tumor 
volume (V) was monitored by measuring the length (L) 
and width (W) with calipers and calculated according to 
the formula (LxW2) x 0.5. After 10 days, tumor-bearing 
mice and controls were sacrificed and the tumors were 
excised and measured. Animals received a standard diet 
and water ad libitum at the Animal Core Facilities of 
the Center for Applied Medical Research (University of 
Navarra). All efforts were made to minimize the suffering 
of the animals.
In silico analysis of the human promoter region 
of SET
For prediction of SET promoter and putative TF 
binding sites within the 2000 bp upstream the TSS of the 
SET transcript (NM_00320X), we used Promoter 2.0 [67], 
ElDorado (Genomatix Software, GmbH) PromoterScan 
(http://www-bimas.cit.nih.gov/molbio/proscan/), and 
NNPP (http://www.fruitfly.org/sequence/human-datasets.
html) softwares. Then, the analysis was performed with 
MotifScanner program [68]. The promoter region was 
extracted from Ensembl database release 69 [69] and the 
position weight matrixes (PWM) of known transcription 
factor binding sites from the public versions of Jaspar [70] 
and Transfac [71] databases.
Plasmid constructs and luciferase reporter assay
Promoter-luciferase reporter constructs were 
obtained by amplifying several regions of the SET 
promoter from BAC-RP11-216B9 (CHORI, BacPac 
Resources, Oakland, USA). The amplicons were digested 
and cloned into NheI–XhoI sites in the promoterless 
luciferase reporter vector (pGL3-Basic) (Promega, 
Madison, WI, USA). E-box mutants were obtained 
by triple ligation by using the primers listed in the 
Supplementary Table S1 and ligated in a NheI-ApaI 
digested -318-pGL3b vector. Single, double and triple 
mutants were tested. Luciferase activity was measured 
with Dual-Luciferase-Assay kit (Promega) 48h after 
transfection by electroporation of 3x106 HL-60 or HEL 
cells with 5 mg of the promoter-luciferase construct and 1 
mg of pRL-SV40. For the TF silencing experiments, the 
corresponding siRNAs for SP1, MYC, RUNX1, GATA2 
or control were added to the electroporation mix. Firefly 
luciferase activity was normalized to Renilla luciferase 
signals to adjust the variability in transfection efficiencies. 
To study the effect of RUNX1 and GATA2 on the SET 
promoter, 100.000 HEK293t cells were transfected using 
the phosphate calcium method with 100 ng of pGL3-
construct and 10 ng of pRL-SV40, together with 445 ng 
each of RUNX1 and GATA2 expression plasmids or 890 
ng of empty vector.
Chromatin immunoprecipitation
Chromatin from crosslinked HL-60 and HEL cells 
was sonicated, pre-cleared and incubated overnight with 
3 mg of the corresponding antibody in RIPA buffer, and 
precipitated with protein G/A-Sepharose. For the re-
ChIP assay, three fourth of the sample were incubated at 
37°C for 30min in 10mM DTT. Supernatants were then 
incubated with the second antibody overnight, and protein 
G/A-Sepharose beads were added for two hour at 4°C the 
following day. The DNA-protein-antibody complexes 
were then washed three times with RIPA, three times with 
RIPA and NaCl, twice with Litium Buffer, and twice with 
1X TE. Cross-linkage of the co-precipitated DNA–protein 
complexes was reversed and DNA was used as a template 
for quantitative Real Time PCR. Primers are listed in the 
Supplementary Table S1.
Immunoprecipitation
Cell pellets were lysed in 3 ml of co-IP buffer 
(PBS containing 0.5% Triton X-100, 1mM EDTA, 
100 μM sodium orthovanadate, 0.25 mM PMSF and 
complete protease inhibitor mixture, Roche). After 
centrifugation, protein samples were quantified by 
the BCA method. Overnight pre-clearing with non-
specific IgG plus protein A/G beads was performed; 
then 1 mg protein was incubated with 5 mg of antibody 
crosslinked to protein A/G-Dynabeads following 
manufacturer’s instructions (Invitrogen). The 
immunocomplexes were extensively washed with co-
IP buffer and subsequently eluted with 50 mL of 0.1M 
Citrate pH 2.5 and boiled at 100°C in Laemmli buffer 
(2X) for Western blot analysis. IP control samples were 
incubated with irrelevant crosslinked IgG.
Western blot analysis
For protein expression studies, 30 mg total protein 
lysates were separated in a 10-12% SDS-PAGE gradient 
gel and transferred onto a PVDF membrane. Overnight 
incubation at 4°C with primary antibodies was performed 
followed by the incubation with the appropriate secondary 
antibodies conjugated to horseradish peroxidase 
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for 45′ at RT. The protein levels were detected by 
chemiluminescence (ECL kit, GE Healthcare, USA). 
The list of the primary antibodies used is described in the 
Supplementary Table S2.
PP2A assay
PP2A activity was determined using the PP2A IP 
phosphatase assay kit (Upstate Biotechnology, 17-313). 
Briefly, protein lysates were prepared in TBS 1X, 1% 
Triton and phosphatase inhibitors tablets (Roche). Fifty 
micrograms of protein were immunoprecipitated with 2 
μg of PP2A antibody (1D6; Upstate Biotechnology)and 
25 μL of protein-A-agarose beads for 2 hours at 4°C. 
After extensive washing with TBS first and with Ser/
Thr assay buffer last, the beads were then used in the 
phosphatase reaction for measuring dephosphorylation 
of the phosphopeptide (K-R-pT-I-R-R) with malachite 
green phosphate detection solution, following 
the manufacturer’s instructions. The level of free 
phosphate is then normalized to total amount of 
immunoprecipitated PP2Ac, assessed by densitometry 
analysis of the western blots.
Statistical analysis
Statistical significance of differences between 
means was estimated using Student’s t-test, Mann-
Whitney U test, Oneway or Twoway-ANOVA and 
Bonferroni test, as appropriate. To evaluate the correlation 
analysis between SET and TFs in AML patients, 
Spearman’s rank correlation coefficient was used, 
because the values did not fit the normal distribution. For 
contingency studies on the distribution of frequencies 
of high or low expression of SET and GATA2 in AML 
patients, the Chi square test was applied. Statistical 
analysis was performed using the SPSS 17.0 statistical 
package (Chicago, IL, USA) and GraphPad software 
(Prism, USA). A P-value of 0.05 was considered to be 
significant (*), 0.01 or 0.001 very significant (** or ***).
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